FATE Fate Therapeutics Inc

$FATE Assenagon Asset Management increased its Fate Therapeutics stake by 799.5%, buying 1,165,927 additional shares to own 1.31 million shares valued at approximately $3.1 million. Institutional investors collectively own 97.54% of the company.

$FATE Today's ASN Kidney Week data provides notable updates: a 100% Month 6 renal response in the bendamustine cohort, complete disappearance of the top 50 pathogenic BCR clones, zero ICANS/GvHD across 29 patients, and durable complete renal response through 24 months, which is more than proof of concept for the current potential registrational Phase 2 trial. Accumulate more while you can at such a low price. $LABU Cheers and best of luck to all of us 🤑🤑🤑

$FATE 2.27 or 2.59 doesnt really make a difference until out of that range. in “data loading mode”

$FATE 👈love this here under $3… traded this for years then it went above $120 … full circle… back to loading this one under $3…

$FATE i like this daily candle we are going to post today, typically a reversal signal for FATE the last few years. Also i apologize for my terrible TA and calling the sma at 2.16 the other week. Cant trust AI. I noticed last night its actually around 1.88, and we bounced right off of it today. A close in 1.90s is fine. $2 will come around again as we near Nov

$FATE 🏥 Fate Therapeutics, Inc. presented updated preliminary Phase 1 data for FT819 in active lupus nephritis showing 100% renal response at Month 6 and approximately 50% mean proteinuria reduction with less-intensive bendamustine conditioning. Market-relevant event

$FATE A unanimous preference for FT819 over autologous CAR T emerged, due to immediate access, shorter hospitalization, less intensive preconditioning chemotherapy, and product consistency.

$FATE first CRBU, now ARTV closing up shop on Allo NK cell therapy in RA and other autoimmune diseases after 2 patient deaths (1 from fludarabine and other death possibly unrelated) as well as poor durability. Other Allo companies pivoting to in vivo from Allo recently including CLLS and ACET. Allo companies are dropping fast. Hoping Fate succeeds in this highly competitive space with in vivo.

$FATE circling back in mid November 👇🏽… 2026 Jefferies Global Healthcare Conference Location: London, UK Date: November 16th – 19th

$FATE Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that it is exploring strategic alternatives to maximize stockholder value and plans to discontinue further development activities for its two allogeneic CAR-T cell therapy programs, vispa-cel for the treatment of relapsed or refractory (r/r) B cell non-Hodgkin lymphoma and CB-011 for the treatment of r/r multiple myeloma. In line with this decision, Caribou will implement workforce and cost reductions.

$FATE Gilead reveals partial clinical hold on 2 CAR-T cell therapy trials, the unfortunate loss of its competitors, and the gain of $FATE , the king in autoimmune CAR-Ts will prove itself, long $FATE and wish us the best of luck 🤞🤞🤞$LABU 🤑🤑🤑

$FATE Morning All! Not gonna lie, I’m not happy about pre-market showing us under $2.00. Still holding though…

$FATE What the ICY HELL!?!?!? I stay away from the matket for one day and THIS happens! Who's in charge here? I DEMAND to speak to the manager!!!

$FATE IMO.....Hiring Jamie Harrell as SVP of marketing to build out commercial infrastructure is the exact playbook a biotech uses to de-risk an asset and create leverage for a buyout. However, this could be a multi-year setup, not an immediate catalyst unless upcoming clinical data is an absolute slam dunk next month.....that forces a buyer's hand early. Without that home run, the stock is likely dead money near $2.00 or lower due to a massive catalyst gap. The Phase 2 RECLAIM-LN trial for FT819 isn't slated to finish enrollment until H1 2028, meaning primary 26-week readout data won't arrive until late 2028. With a $30M quarterly burn rate, institutional money will likely stay sidelined until hard results emerge. More critically, if upcoming interim readouts show weak efficacy or severe safety flags, the buyout thesis evaporates and the stock will tank. Barring that slam-dunk data, expect the price to remain range-bound. Good Luck!

$FATE looks like it's going back to 1.5-1.6 levels. Such a crappy company. What a waste of time and money. Lowest levels since June. Ugghhh